Dr. Reddy's launches Bortezomib injection in the US market.

Dr Reddys Laboratories
Dr. Reddy's Laboratories Ltd. announced the launch of Bortezomib for Injection 3.5 mg/vial, approved by the US Food and Drug Administration (USFDA) via a 505(b)(2) new drug application (NOA) pathway for intravenous use only.

Dr. Reddy's Bortezomib for Injection 3.5 mg/vial is for intravenous use only and is indicated for the treatment of adult patients with multiple myeloma and for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy.

"We're pleased to bring this product to market for the customers and patients who will benefit from this cost-efficient alternative in the market place. This is a great addition to our injectable offering in the US market as we continue to augment our portfolio of products in the Hospital segment," Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy's Laboratories said.

Stock view:
Dr Reddys Laboratories Ltd is currently trading at Rs2,879.70, up by Rs20.65 or 0.72% from its previous closing of Rs2,859.05 on the BSE.

The scrip opened at Rs2,860 and has touched a high and low of Rs2,885 and Rs2,859.40 respectively.




About Gosip4U

Gosip4U is the digital wing of india - India's leading media and communications group with its interests spanning across country.

0 comments:

Post a Comment

Please add comment